Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.33), $0.05 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $14.03 million versus the consensus estimate of $9.42 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.